Related Experiment Video

Updated: Jul 14, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Current approaches for risk stratification of infectious complications in pediatric oncology

Christoph Härtel1, Maresa Deuster, Thomas Lehrnbecher

  • 1Department of Pediatric Hematology, Oncology and Immunology, University of Lübeck, Childrens Hospital, Germany. haertel@paedia.ukl.mu-luebeck.de

Pediatric Blood & Cancer
|May 22, 2007
PubMed

Insights

Identifying low-risk pediatric cancer patients with febrile neutropenia can enable early hospital discharge. This review explores clinical and genetic factors for better risk stratification and safer early discharge strategies for these vulnerable patients.

Area of Science:

  • Pediatric Oncology
  • Infectious Diseases
  • Genetics

Background:

  • Infections are a major risk for pediatric cancer patients undergoing cytoreductive therapy, especially those with febrile neutropenia.
  • Current standard care involves prolonged intravenous broad-spectrum antibiotics until fever and neutropenia resolve.
  • Early hospital discharge is a potential safe and effective strategy for select patient subgroups.

Purpose of the Study:

  • To review strategies for risk stratification of pediatric cancer patients with febrile neutropenia.
  • To identify clinical and laboratory parameters for therapeutic management.
  • To explore genetic susceptibility factors for prophylactic approaches.

Main Methods:

  • Review of existing literature on risk stratification for infectious complications in pediatric cancer patients.
  • Analysis of clinical risk parameters and laboratory measures.
  • Discussion of genetic susceptibility factors and their role in prophylactic strategies.

Main Results:

  • Two main strategies for risk stratification are discussed: clinical/laboratory measures and genetic factors.
  • Existing data from multiple small studies suggest potential for early discharge in certain subgroups.
  • A need for a large prospective trial to validate predictive markers is highlighted.

Conclusions:

  • Risk stratification is crucial for optimizing treatment and enabling early hospital discharge in pediatric cancer patients with febrile neutropenia.
  • Combining clinical, laboratory, and genetic markers may improve predictive accuracy.
  • Further large-scale prospective studies are essential to confirm safety and efficacy of early discharge protocols.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...